About 6LETTERS
This is the new healthcare
as defined by 6Letters.
We are building essential infrastructure - not optional services.
Hormones are the earliest signals of change in human
health. Yet healthcare still remains reactive - we seek
care only after symptoms appear.
We are here to change that structure.
Continuous Health, Every Day
Traditional hormone testing comes with high costs,
limited accessibility, and low measurement frequency.
6Letters bridges this gap through continuous
biometric sensing and medical data-driven AI,
reducing barriers to healthcare access and building a
more sustainable model of care.
From Occasional Testing to Essential Infrastructure
Prevention begins with continuous observation.
We read the flow of change - patterns that one-time
tests cannot capture.
Infrastructure for lifelong health management.
One experience can redefine the standard of care.
Mid-to-Long-Term Business Plan
Phase I 2026
- Launch MVP app
- Launch kiosk
- Digital medical device registration (FDA/CE)
- Clinical trials for product advancement
- Secure 6,000 paid subscribers
- Achieve 30,000 cumulative purchases on self-testing platform
Phase II 2027
- Launch female hormone MVP app
- Enhance male hormone UX (hair loss, fitness, etc.)
- Add female hormone kiosk
- Algorithm enhancement clinical trials & hair loss clinical trials
- Expand B2B contracts
- Series A funding: KRW 5 billion / KRW 50 billion valuation
Phase III 2028
- Surpass KRW 30 billion in revenue
- Advanced female UX (fertility, pregnancy testing)
- Clinical trials for early diagnosis/monitoring of premalignant conditions
- Series B funding: KRW 10 billion / KRW 100 billion valuation
Phase IV 2029
- Revenue target: KRW 100 billion
- FDA/CE submission for early cancer diagnosis
- Clinical trials for female conditions (breast cancer, ovarian cancer), infertility
- Development of additional biomarkers (e.g., melatonin)
- Series C funding: KRW 20 billion / KRW 200 billion valuation
IPO by 2030
- Revenue target: KRW 200 billion
- FDA/CE approval for early premalignant diagnosis
- FDA/CE submission for female & infertility indications
- Launch MVP for additional biomarkers (e.g., melatonin)
- IPO